Literature DB >> 15193636

Acceptability of an existing, female-controlled contraceptive method that could potentially protect against HIV: a comparison of diaphragm users and other method users.

Sheryl Thorburn Bird1, S Marie Harvey, Julie E Maher, Linda J Beckman.   

Abstract

OBJECTIVE: The diaphragm, an internal barrier contraceptive device, is a candidate for a female-controlled method for preventing human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs). This study's objective was to examine how women who use the diaphragm differ from women using the pill and/or condoms with respect to factors hypothesized to influence the acceptability of contraceptive methods. Our goal was to increase understanding of who finds the diaphragm acceptable and why.
METHODS: We conducted a cross-sectional telephone survey with selected female members of a managed care organization. For this analysis, we limited the sample to 585 women currently using the diaphragm (n = 196), pill (n = 200), condoms (n = 132), or pill and condoms (n = 57). We conducted bivariate analyses and multinomial logistic regression analyses to assess the associations between selected characteristics and diaphragm use.
RESULTS: Diaphragm use was significantly associated with several variables. Of particular interest, placing less importance on hormonal method characteristics was significantly associated with diaphragm use (versus use of the pill, condoms, or both). Placing more importance on barrier method attributes was significantly associated with diaphragm use (versus pill use, alone or with condoms). In addition, lower condom use self-efficacy was significantly associated with diaphragm use (versus condom use, alone or with pill). Lack of motivation to avoid HIV/STIs was significantly associated with using the diaphragm versus condoms (only).
CONCLUSION: These results have important implications for future research, interventions, counseling strategies for providers, and product development. Our findings suggest that if the diaphragm protects against HIV, it could be a desirable option for some women.

Entities:  

Mesh:

Year:  2004        PMID: 15193636     DOI: 10.1016/j.whi.2004.03.003

Source DB:  PubMed          Journal:  Womens Health Issues        ISSN: 1049-3867


  6 in total

1.  Acceptability and feasibility of continuous diaphragm use among sex workers in Madagascar.

Authors:  F Behets; A Norris Turner; K Van Damme; N L Rabenja; N Ravelomanana; K Zeller; J R Rasolofomanana
Journal:  Sex Transm Infect       Date:  2005-12       Impact factor: 3.519

Review 2.  Moving beyond safe sex to women-controlled safe sex: a concept analysis.

Authors:  Kamila A Alexander; Christopher L Coleman; Janet A Deatrick; Loretta S Jemmott
Journal:  J Adv Nurs       Date:  2011-11-23       Impact factor: 3.187

3.  Vaginal microbicide and diaphragm use for sexually transmitted infection prevention: a randomized acceptability and feasibility study among high-risk women in Madagascar.

Authors:  Frieda M Behets; Abigail Norris Turner; Kathleen Van Damme; Ny Lovaniaina Rabenja; Noro Ravelomanana; Teresa A Swezey; April J Bell; Daniel R Newman; D'Nyce L Williams; Denise J Jamieson
Journal:  Sex Transm Dis       Date:  2008-09       Impact factor: 2.830

4.  Adherence to diaphragm use for infection prevention: a prospective study of female sex workers in Kenya.

Authors:  Elizabeth A Bukusi; Maria F Gallo; Anjali Sharma; Betty Njoroge; Denise J Jamieson; Rosemary Nguti; April J Bell; David A Eschenbach
Journal:  Infect Dis Obstet Gynecol       Date:  2010-03-07

5.  Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa.

Authors:  Elizabeth T Montgomery; Helen Cheng; Ariane van der Straten; Agnes C Chidanyika; Naomi Lince; Kelly Blanchard; Gita Ramjee; Busisiwe Nkala; Nancy S Padian
Journal:  AIDS Behav       Date:  2009-09-10

6.  Rational Design of a Multipurpose Bioadhesive Vaginal Film for Co-Delivery of Dapivirine and Levonorgestrel.

Authors:  Jing Li; Galit Regev; Sravan Kumar Patel; Dorothy Patton; Yvonne Sweeney; Philip Graebing; Sheila Grab; Lin Wang; Vinayak Sant; Lisa C Rohan
Journal:  Pharmaceutics       Date:  2019-12-18       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.